Masanori Nagata
Overview
Explore the profile of Masanori Nagata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinugasa F, Kajikawa S, Weng J, Ugawa T, Fushiki H, Yamanaka Y, et al.
J Pharmacol Sci
. 2024 Sep;
156(3):161-170.
PMID: 39313274
Claudin-18 splice variant 2 (CLDN18.2), a tight junction protein, is a highly cell type-specific antigen that is expressed by differentiated gastric mucosa cells. The expression of CLDN18.2 in gastric mucosa...
2.
Tang M, Garg A, Bonate P, Rosenberg J, Matsangou M, Kadokura T, et al.
Clin Pharmacokinet
. 2024 Apr;
63(4):423-438.
PMID: 38609704
Enfortumab vedotin is an antibody-drug conjugate comprised of a human monoclonal antibody directed to Nectin-4 and monomethyl auristatin E (MMAE), a microtubule-disrupting agent. The objectives of this review are to...
3.
Matsuda T, Tsunoda I, Nagata M, Kawakita T, Noguchi S
Appl Opt
. 2023 Jan;
61(34):10178-10187.
PMID: 36606779
We experimentally investigate the polarization property of the specularly reflected light from an anodic porous alumina (APA) membrane coated with a gold (Au) thin film. As a result, we reveal...
4.
Walzer M, Marek G, Wu R, Nagata M, Han D
Clin Pharmacol Drug Dev
. 2020 Jan;
9(3):297-306.
PMID: 31926000
ASP8062 is an orally active γ-amino-butyric acid type B (GABA ) receptor positive allosteric modulator currently in phase 2 development. Safety and pharmacokinetic (PK) profiles of ASP8062 were evaluated in...
5.
Lam S, Nagata M, Sandhu S, Veselis R, McCormick P
Br J Anaesth
. 2019 Oct;
123(6):e530-e532.
PMID: 31601359
No abstract available.
6.
Chu J, Nagata M, Chen X, Solomon S, Gonzalez-Aguirre A, Garcia-Aguilar J, et al.
Clin Neurophysiol
. 2016 Jul;
127(8):2770-2772.
PMID: 27417051
No abstract available.
7.
Poondru S, Chaves J, Yuen G, Parker B, Conklin E, Singh M, et al.
Cancer Chemother Pharmacol
. 2016 Mar;
77(4):829-37.
PMID: 26972330
Purpose: This study characterized the pharmacokinetics, mass balance, routes and extent of elimination, metabolites, and safety of a single oral dose of (14)C-linsitinib, an IGF-1R/IR inhibitor, in patients with advanced...
8.
Sato Y, Nagata M, Tetsuka K, Tamura K, Miyashita A, Kawamura A, et al.
Drug Metab Dispos
. 2014 Mar;
42(5):885-9.
PMID: 24595681
The aim of this study was to optimize methods for quantifying 13 uridine 5'-diphosphate-glucuronosyltransferase (UGT) isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17)...
9.
Sato Y, Nagata M, Kawamura A, Miyashita A, Usui T
Xenobiotica
. 2012 Mar;
42(9):823-9.
PMID: 22435749
The aims of this study were to quantify absolute protein levels of uridine 5'-diphosphate-glucuronosyltransferases (UGTs) 1A1 and 2B7 in human liver microsomes (HLMs) and to investigate their correlation with marker...
10.
Takusagawa S, Van Lier J, Suzuki K, Nagata M, Meijer J, Krauwinkel W, et al.
Drug Metab Dispos
. 2012 Jan;
40(4):815-24.
PMID: 22269146
The mass balance and metabolite profiles of 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)[U-(14)C]phenyl]acetamide ([(14)C]mirabegron, YM178), a β(3)-adrenoceptor agonist for the treatment of overactive bladder, were characterized in four young, healthy, fasted male subjects after a...